In December 2015, alectinib became the third ALK inhibitor approved by the United States Food and Drug Administration for the treatment of non-small-cell lung cancer (NSCLC) that displays rearrangements of the anaplastic lymphoma kinase (ALK) gene. Alectinib is a second-generation small molecule inhibitor of the ALK protein that joins ceritinib in providing a useful treatment option for patients who have progressed on crizotinib, as a result of its ability to target crizotinib-resistant mutant forms of the ALK protein. Alectinib also displays enhanced penetrance of the blood-brain barrier, which improves efficacy against central nervous system (CNS) metastases.

The FDA awarded alectinib accelerated approval on the basis of 2 phase 2, single-arm clinical trials in patients with ALK-positive NSCLC who had progressed on crizotinib therapy, a group of patients who have few available treatment options. Full approval is contingent upon the success of the ongoing phase 3 ALEX trial in which alectinib is being compared with crizotinib in chemotherapy-naive patients and for which early results are anticipated in 2018.

The 2 pivotal clinical trials, NP28761 (study 1) and NP28673 (study 2), were conducted at 27 centers in the US and Canada and at 56 centers worldwide, respectively. Study 1 enrolled 87 patients and study 2 138 patients aged 18 years or older, with histologically confirmed, locally advanced or metastatic ALK-positive NSCLC (as confirmed using an FDA-approved ALK testing kit), with measurable disease according to Response Evaluation Criteria in Solid Tumors (version 1.1), and who were previously treated with crizotinib therapy. Eligible patients also had adequate hematologic, hepatic, and renal function, and an Eastern Cooperative Oncology Group performance status of 0-2. Previous chemotherapy was allowed, as were asymptomatic and neurologically unstable, untreated, or treated CNS metastases.

Patients in both studies were treated with 600 mg oral alectinib twice daily until unacceptable toxicity or progression, and underwent tumor imaging at baseline, including computed tomography of the chest and abdomen, as well as brain imaging. Restaging scans and brain scans (for patients with baseline brain metastases) were obtained at regular intervals during treatment.

The primary endpoints were objective response rate (ORR), and secondary endpoints included pharmacokinetic profile, progression-free survival (PFS), overall survival (OS), ORR in the CNS, and safety and tolerability. In both studies, the primary analysis was extended in an updated efficacy analysis. The median duration of follow-up in study NP28761 was 4.8 months in the primary analysis and 9.9 months in the updated analysis, and for NP28673, 30 weeks and 47 weeks, respectively.

Among all patients evaluable for response, ORR was 48% at primary analysis and 52% at updated analysis. The most common side effects are fatigue, constipation, swelling (edema), and muscle pain (myalgia). Treatment with alectinib may cause sunburn when patients are exposed to sunlight, and pregnant women should be notified of the possible risk to the fetus, and to use contraception throughout treatment and for at least 1 week after they receive the last dose.

The US Food and Drug Administration approved alectinib to treat patients with metastatic ALK-positive non-small-cell lung cancer whose disease had progressed or who could not tolerate treatment with crizotinib. In clinical trials, alectinib showed a partial response of 38%-44% and an average progression-free survival of 11.2 months. In all, 61% of patients experienced a complete or partial reduction in their brain metastatic lesions, with a progression-free survival of of 9.1 months. The recommended dose is 600 mg orally twice daily.

What’s new, what’s important
The highly active drug is a very welcome addition to the treatment of ALK-positive lung cancer.
**Mechanism of action: alectinib**

**Challenges of resistance and blood-brain barrier**

The anaplastic lymphoma kinase (ALK) protein is a tyrosine kinase receptor that transmits signals from the cell surface into the cell via a number of important signaling molecules, including the Ras, phosphatidylinositol 3-kinase (PI3K), phospholipase C gamma, and Janus kinase/signal transducer and activator of transcription pathways. Ultimately these signaling cascades activate the transcription of target genes in the nucleus that are involved in key cellular processes, such as proliferation and survival.

The ALK protein can become oncogenic in a number of different ways, but in 3%-7% of patients with non-small-cell lung cancer (NSCLC), this happens when the ALK gene is broken apart and fused to another gene, the echinoderm microtubule-associated protein-like 4 gene, in a process called chromosomal translocation. This results in the expression of a fusion protein and, in this case, the fusion drives the inappropriate activation of ALK’s kinase activity, which promotes cancer cell proliferation and survival.

Following the discovery of the link between ALK gene rearrangements and NSCLC, small molecule inhibitors of ALK were developed in an effort to counteract the effects of oncogenic ALK. These inhibitors block the kinase activity of ALK and prevent downstream signals from being activated. Crizotinib was the first FDA-approved ALK inhibitor and proved superior to chemotherapy in the treatment of advanced ALK-positive NSCLC.

However, patients invariably relapse through a variety of mechanisms, including the acquisition of mutations in the ALK kinase domain that block crizotinib binding. Furthermore, secondary tumors often arise in the central nervous system where crizotinib has limited efficacy due to its poor ability to cross the blood-brain barrier.

Next-generation ALK inhibitors like alectinib have been specifically designed with the ability to target resistant forms of the ALK protein and with improved penetrance of the blood-brain barrier so that they might provide a treatment option beyond progression on crizotinib in this patient population.

In study 1; and 49% and 50%, respectively, in study 2. Median duration of response (DoR) was 13.5 months and 11.2 months in the 2 studies. Among patients with baseline CNS disease, CNS ORR was 75% in study 1 and 57% in study 2, with median DoR of 11.2 months and 10.3 months, respectively. In those with baseline CNS metastases, a CNS complete response was achieved in 29% of patients in study 1 and in 27% of patients in study 2. A pooled analysis of the 2 studies was conducted for 51 patients with CNS metastases. ORR was 61% and CNS complete response rate was 18%, with DoR of 9.1 months. In both studies, fewer CNS progression events were reported compared with non-CNS progression events.

Safety analyses were performed in 253 patients across both clinical trials, with a median duration of exposure to alectinib of 9.3 months. They indicated that adverse events (AEs) were predominantly grade 1 or 2, most commonly constipation, fatigue, and peripheral edema. Serious AEs occurred in 19% of patients and included pulmonary embolism, dyspnea, and hyperbilirubinemia (all 1.2%). Fatal AEs, including hemorrhage, intestinal perforation, dyspnea, pulmonary embolism and endocarditis, occurred in 2.8% of patients overall. Alectinib was permanently discontinued as a result of AEs in 6% of patients initiating treatment at the recommended dose and median time to first dose reduction was 48 days.

The recommended dose for alectinib is 600 mg twice daily with food, administered until disease progression or...
unacceptable toxicity. In the case of AEs, the prescribing information outlines acceptable dose reductions and recommends discontinuing treatment if patients are unable to tolerate a 300-mg dose.

Alectinib is marketed by Genentech as Alecensa. The prescribing information also details warnings and precautions relating to hepatotoxicity, interstitial lung disease/pneumonitis, bradycardia, severe myalgia, creatine phosphokinase (CPK) elevation, and embryo-fetal toxicity. During treatment with alectinib patients should have regular liver function tests, including ALT, AST, and total bilirubin every 2 weeks during the first 2 months of treatment, then periodically thereafter, and more frequently in patients who exhibit elevated levels. Based on the severity of the elevation, treatment can be withheld and resumed or permanently discontinued.

Practitioners should promptly investigate any worsening of respiratory symptoms that may indicate interstitial lung disease/pneumonitis and alectinib should be immediately withheld and subsequently permanently discontinued in the case of a positive diagnosis. Heart rate and blood pressure should be monitored regularly and alectinib withheld for symptomatic cases of bradycardia that is not life-threatening or permanently discontinued following recurrence or in life-threatening cases.

CPK levels should be assessed every 2 weeks for the first month and then as clinically indicated in symptomatic patients and, based on the severity of the elevation, alectinib treatment should be withheld and then resumed or the dose reduced. Patients taking alectinib are advised to avoid sun exposure and to use broad-spectrum sunscreen and pregnant women should be advised of the potential risk to a fetus and to use effective contraception during treatment and for at least 1 week after the last dose.

References